The Technical Analyst
Adhera Therapeutics, Inc. [ATRX]
Exchange: PNK Industry: Biotechnology
Adhera Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0060
America/New_York / 3 mai 2024 @ 14:09
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.0433 mill |
| EPS: | -1.170 |
| P/E: | -0.0100 |
| Earnings Date: | May 20, 2024 |
| SharesOutstanding: | 7.22 mill |
| Avg Daily Volume: | 0.0856 mill |
| RATING 2024-05-03 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0100 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0100 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0040 - 0.0080 ( +/- 33.33%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-04-20 | Waerness Trond Kydd | Buy | 0 | |
| 2021-11-05 | Subhan Zahed | Buy | 0 | |
| 2020-07-07 | Kucharchuk Andrew Albert | Buy | 0 | |
| 2019-11-01 | Stanley Rhonda L. | Buy | 350 000 | Options to purchase common stock |
| 2019-11-01 | Stanley Rhonda L. | Buy | 0 |
| INSIDER POWER |
|---|
| 0.00 |
| Last 84 transactions |
| Buy: 54 073 796 | Sell: 917 096 |
Forecast:
15:49 - $0.0060
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0060 (0.00% ) |
| Volume | 0.0120 mill |
| Avg. Vol. | 0.0856 mill |
| % of Avg. Vol | 14.03 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ATRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ATRX
Adhera Therapeutics, Inc. focuses on the discovery and development of drugs. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
Latest Press Releases
2021-10-15 10:21:00 - Press Release
Manufacturing Commences On Adhera's Mlr-1019 For Phase 2a Clinical Trial Treating Parkinson's Disease
Ip estate grows with new korean patent issued
2021-10-04 09:15:00 - Press Release
Adhera Receives European Patent Covering Mlr-1019 And Derivatives For Treating Dyskinesias
Baton rouge, la, oct. 04, 2021 (globe newswire) -- adhera therapeutics, inc. (otcpk: atrx) ("adhera" or the "company"), a clinical stage biopharmaceutical company, is pleased to announce that a new european patent has been issued for mlr-1019 (armesocarb), a drug licensed by the company from melior discovery (“melior”) company melior pharmaceuticals ii, llc (“melior 2”). melior has received notice from the european patent office that the patent, titled, “methods of treating dyskinesia and related disorders,” passed the required period without any opposition being filed, triggering the issuance of the patent.
Latest News
2021-10-15 10:21:00 - GlobeNewsWire
Manufacturing Commences on Adhera's MLR-1019 for Phase 2a Clinical Trial Treating Parkinson's Disease
2021-10-14 09:25:31 - InvestorPlace
7 Biotech Penny Stocks With Huge Catalysts Coming in 2022
With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 appeared first on InvestorPlace.
2021-10-04 09:15:00 - GlobeNewsWire
Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias
Baton Rouge, LA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new European patent has been issued for MLR-1019 (armesocarb), a drug licensed by the Company from Melior Discovery (“Melior”) company Melior Pharmaceuticals II, LLC (“Melior 2”). Melior has received notice from the European Patent Office that the patent, titled, “Methods of Treating Dyskinesia and Related Disorders,” passed the required period without any opposition being filed, triggering the issuance of the patent.